Secondary prevention of cardiovascular disease after carotid endarterectomy should include management of low-density lipoprotein (LDL) levels, but increased LDL levels are undertreated in these patients. We examined trends in statin use and LDL goal achievement in veterans undergoing carotid endarterectomy (CEA), a medically high-risk group with high rates of cardiovascular morbidity and mortality. The records of all CEA performed between 1995 and 2005 in the Connecticut Veterans' Affairs (VA) hospital were reviewed. Kaplan-Meier analysis was used to analyze long-term outcomes. ANOVA was used for comparisons between groups. A total of 309 CEA procedures were performed in 298 patients. The mean follow-up was 4.1 years. Statin use increased over time (12% in 1995, 84% in 2005) and mean LDL levels decreased (105 mg/dl in 1997, 90 mg/dl in 2007). The number of patients achieving LDL goals of 100 mg/dl or 70 mg/dl increased. Mean HDL levels decreased (53 mg/dl in 1997 and 38 mg/dl in 2007). Patients with three or more comorbid medical conditions were more likely to achieve LDL goals. At 12 years, freedom from stroke was 91%, freedom from myocardial infarction was 46% and survival was 12%. In conclusion, over the last decade, among patients who have undergone CEA, statin use has increased and LDL levels have improved.
Introduction
Atherosclerotic disease is a systemic condition, characterized by multiple lesions leading to end organ impairment. Therefore, patients undergoing carotid endarterectomy (CEA) may harbor disease in several arterial beds. Patients with arterial disease have been shown to have decreased life expectancy, 1 increased cardiovascular mortality, 2 and elevated rates of chronic kidney disease and functional impairment. 3 The beneficial effects of statins have been well documented in coronary artery disease (CAD) prevention, 4 but patients with peripheral arterial disease (PAD) remain undertreated. CEA patients may benefit from secondary prevention with statins.
The American Heart Association has recommended strict modification of atherosclerotic risk factors, including a low-density lipoprotein (LDL) goal of < 100 mg/dl. 5 The National Cholesterol Education Program (NCEP) recommends that for highrisk patients (patients with CAD, non-coronary atherosclerotic disease, diabetes or multiple cardiovascular risk factors) a LDL goal of < 70 mg/dl is a therapeutic option. 6 Previous studies have shown that lipid-lowering therapy with HMG-CoA reductase inhibitors, or 'statins', is associated with a reduction in stroke, cardiovascular mortality and overall mortality. 7 Aggressive therapy has been shown to have greater benefit than moderate therapy, with patients benefiting from lowering LDL levels well below 100 mg/dl. 8, 9 However, it has also been shown that atherosclerotic risk factors are undertreated in patients with vascular disease. 10, 11 Patients treated at Veterans' Affairs (VA) hospitals have traditionally been thought by the medical community to have increased numbers of comorbid medical conditions compared with patients not treated in VA hospitals, and may have high rates of cardiovascular disease. We have recently shown that patients treated with CEA in VA hospitals have a greater number of comorbid conditions and form a medically high-risk group, 12 compared with a matched group of patients treated with CEA outside of the VA system. 13 Therefore, to determine the predictors of LDL goal achievement and the effects of lipid-lowering therapy in high-risk patients, we examined statin usage and LDL levels in veterans treated with CEA. It was our hypothesis that statin usage would increase and that LDL levels would improve over time.
Methods
Using ICD-9 codes, all CEA procedures performed at the VA Connecticut Healthcare Systems between January 1995 and December 2005 were identified within the VA database. Perioperative demographics, comorbid medical conditions, laboratory values and long-term outcomes were obtained via systematic electronic chart review. Cause of death was determined from chart review and verified by examination of death certificates (Department of Vital Records, State of Connecticut). This study was approved by the Institutional Review Board at the West Haven VA Medical Center.
Preoperative demographic and clinical variables were recorded for each patient and included age, sex, race, CAD, PAD exclusive of carotid disease, diabetes, hypertension (HTN), smoking history and renal disease. PAD was defined as the presence of aortic aneurysm, renal artery stenosis, claudication, rest pain or ulceration secondary to arterial compromise. CAD was defined as coronary disease diagnosed by imaging or stress testing, or previous percutaneous coronary intervention with balloon angioplasty or stenting, or coronary artery bypass grafting. Renal disease was defined by a creatinine value > 1.5 mg/dl. Patients were considered asymptomatic at presentation for CEA if there was no history of stroke, transient ischemic attack (TIA), amaurosis fugax or Hollenhorst plaques. Stroke was defined as an ischemic neurologic event resulting in a permanent functional deficit. Preoperative laboratory values, including albumin and creatinine, and medications were recorded. Long-term outcomes included any neurological event, ischemic cardiac event (defined as ECG changes or elevation of cardiac enzymes) or death that occurred before April 1, 2007 . Postoperative variables were recorded as the value at the most recent follow-up and included systolic blood pressure, diastolic blood pressure, body mass index (BMI), hemoglobin A1C, total cholesterol, triglycerides, high-density lipoprotein (HDL) and low-density lipoprotein (LDL).
Patients were considered to have met the standard LDL goal if their most recent LDL level was below 100 mg/dl and were considered to have met a more stringent LDL goal if below 70 mg/dl. Kaplan-Meier analysis was used to evaluate survival, freedom from stroke and freedom from myocardial infarction. ANOVA was used to compare groups (Stat-View, version 5.0; SAS Institute Inc.). A p-value < 0.05 was considered statistically significant.
Results

Patient demographics
Over a 5-year period, 309 CEA procedures were performed in 298 patients at the VA Connecticut Healthcare System. Thus, the total sample size was 298. Patient follow-up was 100% and the mean time of follow-up was 4.1 years (range 0.03-12 years).
The majority of patients in the study were white males, and there were high rates of comorbid conditions (Table 1) . At presentation for CEA, 85% of patients had a history of hypertension, 40% carried a diagnosis of diabetes, 78% had a smoking history, and 26% were current smokers. Coronary artery disease was present in 59% and 39% of patients had previously undergone either coronary artery bypass Trends in statin use Statin use has increased over time. In 1995, only 12% of patients presenting for CEA were prescribed a statin ( Figure 1 ). The number of patients treated with statins progressively increased and then leveled off between 2001 and 2005, with an average of 84% of patients being prescribed a statin. Peak use occurred in 2001, when 94% of patients were prescribed a statin.
Trends in lipid goal achievement
This increase in statin use has resulted in improved LDL profiles. Figure 2 shows the trend in most recently measured LDL and HDL levels as a function of time. LDL levels have steadily decreased, decreasing from an average LDL of 105 mg/dl in 1997 to 90 mg/dl in 2007. However, HDL levels have also decreased. The average HDL was 53 mg/dl and 38 mg/dl in 1997 and 2007, respectively.
More patients are achieving goal LDL. In this study, 190 patients (64%) achieved a goal LDL of less than 100 mg/dl (LDL of 0-99 mg/dl) and 65 patients (22%) achieved an LDL of less than 70 mg/dl (LDL of 0-69 mg/dl). The percentage of patients achieving goal LDL increased with time ( Figure 3 ). In 1997, only 37% and 12% of patients were achieving LDL goals of less than 100 mg/dl and 70 mg/dl, respectively. That number steadily increased, and currently, in 2007, 74% achieved a goal of less than 100 mg/dl. In 2005, 30% achieved an LDL of less than 70 mg/dl, but this number declined to 24% in 2006 and 10% in 2007.
Patients with comorbidities were more likely to achieve LDL goals (Figure 4) . Patients were assigned one point for each comorbid condition of CAD, PAD, hypertension, diabetes or renal disease. Lipid levels tended to decrease as the number of comorbid conditions increased. Patients with zero or one comorbidity had an average LDL level of 100 mg/dl, whereas patients with five comorbidities had an average LDL level of 79 mg/dl. Patients with three or more comorbid conditions were more likely to achieve lipid goals than patients with two or 
Long-term outcomes
Long-term events were analyzed using Kaplan-Meier analysis ( Figure 5 ). There were 14 ipsilateral strokes (5%), 26 total strokes (9%) and 41 myocardial infarctions (14%) over the 12-year follow-up period. Therefore, freedom from ipsilateral stroke was 95%, freedom from stroke was 91% and freedom from myocardial infarction was 46%. There were 99 deaths (33%). The 5-year survival was 71%, 10-year survival was 33%, and 12-year survival was 12%. The causes of death for patients in the study are listed in Table 2 . The most common cause of death was cancer, accounting for 21% of the deaths in the study. Patients also died from CAD (20%), pulmonary disease (15%), renal failure (5%), stroke (4%) and other PAD (3%). Therefore, at least 27% of deaths were directly related to atherosclerosis. In 13 patients, a cause of death could not be determined from the electronic medical record or death certificate. There were no inconsistencies found in cause of death between chart review and death certificate data.
Discussion
We demonstrate that patients treated with CEA in VA hospitals in the state of Connecticut had increased statin use over time. These patients also had improved LDL levels, with more patients achieving both standard and more stringent LDL goals over time. Patients with more comorbid conditions were more likely to achieve LDL goals. 
Lipid-lowering therapy trends are improving
Previous studies have shown that arterial disease is undertreated by general practitioners, 10, 11 and patients with a history of CAD are more likely to receive lipid-lowering therapy, 14, 15 and that the diagnosis of dyslipidemia is often ignored in patients with PAD. 16 Furthermore, large portions of highrisk patients are currently undertreated for dyslipidemia. 17 In this study of medically high-risk patients at the VA, we did not find this to be the case. During the later years of the study, 76-94% of patients were prescribed a statin, which is quite high. These patients were well treated compared with other non-clinical trial observational reports. 18, 19 Therefore, trends in lipid-lowering therapy initiation are improving, likely as a result of increased practitioner awareness of the benefits of statin use, the increased awareness of the morbidity and mortality associated with cardiovascular disease or more recent changes in guidelines allowing practitioners to target an LDL less than 70 mg/dl in high-risk patients. This most likely represents the work of primary care physicians, who generally are responsible for prescribing statins for this population at the VA. The increased awareness is likely due to recent clinical trials showing the benefits of statin therapy. 20, 21 Unfortunately, while LDL levels decreased, HDL levels also decreased. It is unknown why HDL levels decreased in this study. Statins have been shown to effectively lower LDL levels, but they do not increase HDL levels. Previous studies have shown that in populations where LDL levels have been effectively lowered, HDL levels still remain low. Low HDL levels have been attributed to a decreased emphasis on fibrates, niacins, and n-3 fatty acid preparations. 22 Diet modification should also be emphasized in clinical practice, as it has been shown to reduce LDL levels, increase HDL levels, Figure 5 Kaplan-Meier curves for stroke, myocardial infarction and death. Freedom from ipsilateral stroke was 95%, freedom from stroke was 91% and freedom from myocardial infarction was 46%. The 5-, 10-, and 12-year survival was 71%, 33%, and 12%, respectively. (MI, myocardial infarction.) and results in weight loss. 23 As new therapies aimed at HDL levels emerge, clinicians must stay abreast of current lipid-modifying strategies. 24 Smoking cessation 25 and exercise 26 have been shown to improve HDL levels, while obesity has been shown to have a negative effect. 27 It is possible that these factors may have contributed to the decreased HDL levels in this study.
Multiple comorbidities associated with lower LDL levels
Patients with comorbidities were more likely to achieve LDL goals than healthier patients, and the more comorbid conditions that were present, the lower the LDL levels. This trend is likely the result of practitioner awareness and patient compliance.
Patients with multiple comorbidities are likely to be seen by their primary care physician more often, and primary care providers may have a heightened awareness to prescribe a statin when patients are more ill.
High rates of myocardial infarction
Despite increases in statin use and the achievement of LDL goals, there was a high rate of myocardial infarction (MI). A total of 20 patients died of CAD during this study, and freedom from MI was only 46% at 12 years. Given the high-risk nature of this patient population, this is not a surprising outcome. However, it does illustrate the need for secondary prevention of cardiovascular mortality in the CEA patient. This prevention strategy will likely need to incorporate multiple modalities, as our data suggest that decreased LDL levels alone are not sufficient to treat CAD and prevent MI. Since the focus of our study was on statin use and LDL goal attainment, we did not investigate the trends in usage of other medications that may be useful in preventing myocardial infarction: beta-blockers, angiotensin converting enzyme inhibitors, aspirin, and other anti-platelet medications. Similarly, we were unable to ascertain smoking cessation rates, diet modification, and changes in exercise patterns over time. Future studies are needed to ascertain how medical manipulation of these non-lipid risk factors affects outcomes in these patients.
Limitations
This study is limited by its retrospective nature. The uncertain cause of death in 13 patients occurred when the patient died at a non-VA system hospital, outside of Connecticut. It is possible that some of these 13 patients died of stroke or CAD. LDL levels were taken as the most recent value recorded. It is unknown how many of these levels represent a true fasting serum measurement. This study also did not take into account multiple lipid measurements in a given patient or trends in lipid levels within a patient over time.
Some patients may require high dosages of statins in order to achieve LDL goals, and these dosages may be associated with an increase in side effects, particularly musculoskeletal and hepatic toxicity. 28 This study did not investigate statin dosage or the incidence of side effects in this population.
Conclusions
We demonstrate that patients treated with CEA in VA hospitals in the state of Connecticut had increased statin use over time. These patients also had improved LDL levels, with more patients achieving both standard (< 100 mg/dl) and more stringent (< 70 mg/dl) LDL goals over time.
Patients with more comorbid conditions were more likely to achieve LDL goals. While LDL levels decreased, HDL levels also decreased. These results suggest that while there remains a need to target HDL, the diagnosis and treatment of hyperlipidemia in this high-risk population undergoing CEA has improved over time.
